Danish Pharmacovigilance Update, 21 February 2013

25 April 2013

In this issue of Danish Pharmacovigilance Update:

  • Cardiovascular monitoring when initiating and re-initiating treatment with fingolimod (Gilenya®) (front page)
  • Adverse Drug Reaction Manager assists the Capital Region of Denmark with adverse reaction reporting (p 2)
  • Liver function monitoring recommended due to the risk of liver diseases from the use of Revlimid® (lenalidomide) (p 3)
  • Reports of adverse reactions concerning psychological changes in patients treated with levodopa (p 3)
  • Doctors in Denmark continue to follow recommendations for contraceptive pills (p 4)
  • The European Pharmacovigilance Risk Assessment Committee (PRAC) is reviewing the safety of acne medicines containing cyproterone and oestrogen (Diane® Mite and others) (p 5)
  • Risk of cardiovascular adverse reactions in patients with essential thrombocythaemia (ET) in association with anagrelide hydrochloride (Xagrid®)m (p 6)
  • Direct safety information (DHPC*) for doctors and other healthcare professionals will be made available on the Danish Health and Medicines Authority's website (p 7)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.